CTI BioPharma is an American biopharmaceutical company that specializes in developing and commercializing targeted therapies for blood-related cancers, with a focus on novel drugs. Its flagship product, VONJO (pacritinib), is an oral kinase inhibitor designed to treat adult patients with myelofibrosis, which targets JAK2, FLT3, IRAK1 and CSF1R. Formerly known as Cell Therapeutics, the company has license and collaboration agreements with S*BIO Pte Ltd., Teva Pharmaceutical Industries Ltd., and Baxalta.